(NASDAQ: UTHR) United Therapeutics's forecast annual revenue growth rate of 11.8% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.3%.
United Therapeutics's revenue in 2026 is $3,182,700,000.On average, 17 Wall Street analysts forecast UTHR's revenue for 2026 to be $148,400,544,796, with the lowest UTHR revenue forecast at $132,184,300,976, and the highest UTHR revenue forecast at $160,759,952,248. On average, 17 Wall Street analysts forecast UTHR's revenue for 2027 to be $169,437,834,076, with the lowest UTHR revenue forecast at $139,985,629,084, and the highest UTHR revenue forecast at $199,065,349,812.
In 2028, UTHR is forecast to generate $196,085,067,164 in revenue, with the lowest revenue forecast at $146,296,815,868 and the highest revenue forecast at $229,087,314,722.